AMG 193 + RMC-6236

**AMG 193 + RMC-6236** is an experimental combination therapy being investigated for advanced solid tumors, particularly those with methylthioadenosine phosphorylase (MTAP) deletion, including gastrointestinal, biliary tract, and pancreatic cancers. - **AMG 193** is an orally bioavailable, small molecule, MTA-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to induce synthetic lethality in MTAP-deleted tumor cells by selectively inhibiting PRMT5 activity in the presence of MTA. - **RMC-6236** (daraxonrasib) is a small molecule pan-RAS(ON) inhibitor targeting activated RAS proteins, including KRAS-mutant tumors, and blocks downstream oncogenic signaling (notably the RAS-MEK-ERK pathway). Preclinical and early clinical research suggests potential synergistic antitumor effects when administered together, particularly for MTAP-deleted cancers[3][5][7].